ProfileGDS5678 / 1428631_a_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 95% 95% 96% 96% 95% 95% 95% 96% 97% 96% 95% 95% 95% 96% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 18.4949495
GSM967853U87-EV human glioblastoma xenograft - Control 28.6393895
GSM967854U87-EV human glioblastoma xenograft - Control 38.8841996
GSM967855U87-EV human glioblastoma xenograft - Control 48.8617996
GSM967856U87-EV human glioblastoma xenograft - Control 58.6940195
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 18.3409695
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 28.0920995
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 38.6907996
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 49.0151697
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 18.6707196
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 28.4472795
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 38.6412695
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 48.3647995
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 58.6915396